Related Experiment Video

Updated: Dec 18, 2025

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.8K

Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV

Ruzica Lukic1, Maja Cupic2, Nevena Gajovic3

  • 1Department of Microbiology, Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina. l.ruzica@yahoo.com.

Journal of Infection in Developing Countries
|June 12, 2020
PubMed

Insights

Elevated soluble ST2 (sST2) levels in patients with end-stage renal disease (ESRD) and Hepatitis C Virus (HCV) infection may indicate reduced liver damage. This suggests the IL-33/ST2 pathway influences liver disease severity in these patients.

Area of Science:

  • Immunology
  • Hepatology
  • Nephrology

Background:

  • Hepatitis C Virus (HCV) is a major cause of chronic liver disease globally.
  • HCV infection is common in end-stage renal disease (ESRD) patients due to factors like blood exposure and hemodialysis.
  • The IL-33/ST2 signaling pathway's role in HCV and ESRD co-infection is not well understood.

Purpose of the Study:

  • To investigate the impact of the IL-33/ST2 signaling pathway on liver disease severity in ESRD patients with HCV infection.
  • To compare sST2 levels and ratios with inflammatory cytokines in different patient groups.

Main Methods:

  • Blood samples were collected from 20 ESRD HCV+ patients, 20 HCV+ patients, and 20 healthy controls.
  • Biochemical parameters, serum cytokine concentrations (including sST2), and HCV molecular diagnostics were analyzed.

Main Results:

  • Serum sST2 levels positively correlated with urea and creatinine.
  • sST2 levels were significantly higher in ESRD HCV+ patients compared to HCV+ patients.
  • Ratios of sST2 to IL-1, IL-4, and IL-23 were elevated in ESRD HCV+ patients, indicating altered pathway activity.

Conclusions:

  • Elevated sST2, potentially due to renal failure, may be associated with less liver destruction in HCV infection.
  • The IL-33/ST2 pathway plays a role in modulating liver disease severity in co-infected ESRD patients.
Abstract

Keywords:
HCVend-stage renal diseasesST2

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.8K
Heterotopic Auxiliary Whole Liver Rat Transplant Model Utilizing a Hepaticoureterostomy for Allograft Rejection Studies11:25

Heterotopic Auxiliary Whole Liver Rat Transplant Model Utilizing a Hepaticoureterostomy for Allograft Rejection Studies

Published on: March 8, 2024

727

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
116
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
148
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
122
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
448
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
711
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
347